Cell therapies, including CAR and TCR T-cell approaches, have proven to be highly effective in treating hematologic tumors. Assays of efficacy and activity in T-cell recruitment and tumor cell killing are important for understanding therapeutic mechanisms of action.
This white paper describes how ACD’s RNAscope ISH technology allows engineered T-cells to be detected and quantified in the tumor microenvironment or any other intact tissue. The high sensitivity of the RNAscope assay enables pre-clinical screening for target antigen expression at the RNA level to avoid adverse effects resulting from on-target/off-tumor activity.
Offered Free by: ACD
See All Resources from: ACD